Next-generation maturation inhibitor BMS-955176 shows good antiviral activity in combination with atazanavir
Intermittent PrEP may be a robust strategy for anal sex – vaginal much less certain
START trial provides definitive evidence of the benefits of early HIV treatment
Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing
Targets proliferate in HIV cure research
Young woman stays undetectable for twelve years off treatment after early HIV therapy
World Health Organization to recommend HIV treatment for all
